Attune Neurosciences treats the brain with sound.

Focused ultrasound is not a new idea, which is part of what makes Attune Neurosciences worth paying attention to. The same physics that lets a prenatal scan look inside a body can, when you focus and tune it carefully, deposit energy at a precise point deep in tissue. Surgeons have used high-intensity versions of this to ablate brain tissue and stop essential tremor - in an MRI machine, in a hospital, with a lot of equipment. It works. It is also expensive, immobile, and about as far from wearable as a technology can get.

Attune's bet, founded in 2019, is that you can turn the power way down - to what the field calls low-intensity focused ultrasound, or LIFU - and instead of destroying tissue, gently nudge neurons on or off. And if you can do that at low power, the argument goes, you can eventually do it with something a person wears rather than something a hospital owns. That device is called ATTN201, and it is a headband.

What the headband does is more clever than a headband has any right to be. It steers ultrasound toward deep brain targets while simultaneously recording EEG and head movement through on-device electrodes and an accelerometer. In other words it is both the intervention and the instrument measuring the intervention, which is the sort of closed-loop arrangement that makes a company's clinical data much more interesting than a black box that simply buzzes and hopes.

The target Attune keeps returning to is a structure called the central medial thalamus. It is roughly grape-sized, sits deep in the middle of the brain, and plays a genuine role in flipping the switch between sleep and wakefulness. Hitting it non-invasively is hard - which is precisely why a company gets built around doing it. Anyone can affect the brain crudely. The engineering, and the business, is in the aim.

Now, the honest part. If you go to Attune's website looking for a miracle, you will instead find the word investigational. ATTN201 is not FDA-approved. It is a research tool running clinical trials, and the company says so plainly - a registered study of transcranial focused ultrasound safety at the central medial thalamus, feasibility work on wearing the device overnight for people in recovery from opioid use disorder, a 2025 preprint on ultrasound for REM sleep enhancement. This is the unglamorous middle of the story, where the promise either becomes evidence or it does not.

It is also, quietly, the most credible thing about the company. Health tech has a well-earned reputation for over-promising, and a company that leads with “we are still proving this” is doing something countercultural in a market that usually does the opposite. Trust, it turns out, is built as much on what you decline to claim as on what you announce.

The problem Attune is really attacking is a distribution problem wearing a lab coat. Depression, addiction, insomnia and chronic pain look like different conditions, but Attune is betting several of them share an address deep in the brain - and that the reason deep brain therapy still happens in hospitals is form factor, not biology. Shrink the machine into a headband and the question stops being “can we reach this target” and becomes “can we reach it from someone's bedroom.”

That is a big idea, and big ideas are cheap. What is expensive - and what Attune is actually spending its time on - is the proof: the transducer patents, the targeting algorithms, the trials with clinical registry numbers, the collaborators with acronyms like DARPA, NIH and USSOCOM who do not lend their names to vaporware. Fifteen people, one headband, and a very serious list of institutions watching to see whether sound can do what chemistry and surgery have not.